lapatinib has been researched along with ibandronic acid in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (ibandronic acid) | Trials (ibandronic acid) | Recent Studies (post-2010) (ibandronic acid) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 794 | 184 | 306 |
| Protein | Taxonomy | lapatinib (IC50) | ibandronic acid (IC50) |
|---|---|---|---|
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.4112 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for lapatinib and ibandronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for lapatinib and ibandronic acid
| Article | Year |
|---|---|
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab | 2005 |